EUCTR2019-001655-39-ES进行中（未招募）1 期
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Versus Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer - innovaTV 301
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Genmab A/S
- 入组人数
- 482
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age =18 years (for subjects in Japan, age =20 years).
- •2.Must sign an informed consent form (ICF) indicating that they understand the purpose of and procedures required for the trial and are willing to participate in the trial prior to any other trial-related assessments or procedures.
- •3.Has recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology, and:
- •a.Has experienced disease progression during or after treatment with standard of care systemic therapy defined as either:
- •- paclitaxel+cisplatin+bevacizumab, or
- •- paclitaxel+carboplatin+bevacizumab, or
- •- paclitaxel+topotecan/nogitecan+bevacizumab
- •b.Has received 1 or 2 prior systemic therapy regimens for recurrent and/or metastatic cervical cancer.
- •c.Is not a candidate for curative therapy, including but not limited to radiotherapy or exenterative surgery.
- •5.Acceptable renal function
- •6.Acceptable liver function
- •7.Acceptable hematological status
- •8.Has ECOG PS of 0 or 1 prior to randomization.
- •10.Has a negative serum pregnancy test for female subjects of reproductive potential. Subjects that are postmenopausal or permanently sterilized (refer to Section 10.1.4) can be considered as not having reproductive potential.
- •11.Subjects of reproductive potential must agree to use adequate contraception during and for 6 months after the last trial treatment administration.
- •13.Where required by local health authorities, has negative serology for hepatitis B surface antigen (HBsAg)/HBV DNA, or hepatitis C antibody (HCVAb) or RNA. Active hepatitis C is defined by a known positive HCVAb result and known quantitative HCV RNA results greater than the lower limits of detection of the assay.
- •14.Must provide a fresh or archival biopsy prior to the first planned administration of trial treatment, unless determined it is unfeasible after sponsor medical review.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 386
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 96
排除标准
- •1.Has primary neuroendocrine, lymphoid, sarcomatoid, or other histologies not mentioned in inclusion criterion 3
- •2.Has clinically significant bleeding issues or risks
- •3. Clinically significant cardiac disease
- •5.Ocular surface disease Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or above, any prior episode of cicatricial conjunctivitis, or any prior episode of Stevens-Johnson syndrome.
- •6.Other cancer: known past or current malignancy other than inclusion diagnosis, except for: non-invasive basal cell or squamous cell skin carcinoma; non-invasive, superficial bladder cancer; any curable cancer with a complete response (CR) of =5 years duration.
- •8.Surgery/procedures: major surgery within 4 weeks or minor surgery within 7 days prior to the first trial treatment administration. Subjects must have recovered adequately from the toxicity or complications from the intervention prior to starting trial treatment. Subjects who have planned major surgery during the treatment period must be excluded from the trial.
- •9.Peripheral neuropathy =grade 2.
- •10.Prior anti-cancer therapy:
- •a.Any prior treatment with MMAE-derived drugs.
- •b.Radiotherapy within 21 days prior to the first administration of trial treatment. Subjects must have recovered from all clinically significant radiation-related toxicities. At least 42 days must have elapsed from the last administration of chemo radiotherapy.
- •c.Is currently participating in or has participated in a trial of an investigational agent or device and received active treatment within 28 days prior to the first dose of trial treatment.
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical CancerEUCTR2019-001655-39-FISeagen Inc.482
招募中
1 期
A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical CancerCTIS2023-503813-31-01Seagen Inc.480
进行中（未招募）
1 期
A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical CancerEUCTR2019-001655-39-HUSeagen Inc.482
进行中（未招募）
1 期
A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical CancerSecond- or Third-Line Recurrent or Metastatic Cervical CancerMedDRA version: 21.1Level: PTClassification code 10008342Term: Cervix carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001655-39-SESeagen Inc.482
进行中（未招募）
3 期
Phase 3 Trial of Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical CancerCervical cancerJPRN-jRCT2011210028iz Whalley50